Investor Presentaiton

5DXd-ADCS Additional updates in clinical studies and regulatory communications Daiichi-Sankyo ENHERTU® ■Jun 2023: Combination study with DS-1103 (anti-SIRPα antibody) started ■Jul 2023: Approved in China for chemo treated HER2 low BC (DESTINY-Breast04) DS-7300 ■ Apr 2023: Orphan drug designation granted by FDA for SCLC BC: breast cancer, FDA: U.S. Food and Drug Administration, SCLC: small cell lung cancer 24

View entire presentation